Systemic lupus erythematosus and thrombosis

Thrombosis Journal

Table 3 Treatment recommendations for patients with SLE, associated or not with aPLs or APS, and thrombosis (modified from [14])

Clinical scenario	Recommendations
Patients with definite APS (+/− SLE) and first venous event	aVK, INR range of 2.0-3.0
Patients with definite APS (+/− SLE) and venous recurrent thromboembolism during aVK or arterial thrombosis*	aVK, target INR > 3.0^a
	or
	combination of aspirin (100 mg daily) and aVK, INR range 2.0-3.0^a
APS patients (without SLE) with a first non cardioembolic cerebral arterial event, low-risk aPL profile, and reversible predisposing factors	Antiplatelet agents
SLE patients with venous or arterial thrombosis who do not fulfil APS laboratory classification criteria	Same as patients from the general population who develop venous or arterial thrombosis

^aThere was a lack of consensus on these recommendations.
APS, antiphospholipid syndrome; INR international normalized ratio; SLE, systemic lupus erythematosus; aPL, antiphospholipid antibodies.

ISSN: 1477-9560